ExploreWatchlistsPricing
  1. JP-listed companies
  2. Eisai Co., Ltd.
  3. Financials
  4. Cash from investing

Eisai Co., Ltd. (4523)

Market cap
¥1.16T
P/E ratio
21.5x
Eisai develops, manufactures and sells prescription drugs and over-the-counter medicines globally across Japan, North America, China, Europe and Asia.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCash from investing (Million JPY)YoY (%)
Mar 31, 2026-41,795+313.93%
Mar 31, 2025-10,097-60.12%
Mar 31, 2024-25,321+11.43%
Mar 31, 2023-22,723-21.23%
Mar 31, 2022-28,848-21.76%
Mar 31, 2021-36,873+33.48%
Mar 31, 2020-27,625+248.89%
Mar 31, 2019-7,918-146.47%
Mar 31, 201817,040-159.59%
Mar 31, 2017-28,596+326.74%
Mar 31, 2016-6,701-64.43%
Mar 31, 2015-18,841-190.21%
Mar 31, 201420,885-0.19%
Mar 31, 201320,925

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat